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CORRESPONDENCE
Letters to the Editor
Diastolic Dysfunction
and Doppler Echocardiography
The recent review by Maurer et al. (1) on diastolic dysfunction was
a welcome read. I concur completely with their observations that
“have led us to fundamentally question whether diastolic dysfunc-
tion is the underlying pathologic mechanism of the heart failure
syndrome in all hypertensive patients with “heart failure with a
normal ejection fraction” (HFNEF).” Our group has also come to
the same conclusion. We showed some time ago that systolic
function is not normal in patients with “diastolic heart failure” or
HFNEF when more sensitive measures of left ventricular long axis
function are made by tissue Doppler recording of the mitral valve
annulus (2). These findings have now been confirmed by others.
We also found that early diastolic filling velocities are closely
related to those of systole (3), supporting the view that the most
important determinant of early diastolic filling is in fact the
previous systole. The Torrent-Guasp concept of ventricular con-
traction (4) provides an elegant explanation for why systole is so
closely related to early diastolic filling because the latter is in fact
a systolic phenomenon. Perhaps what was missing in this review
was the concept of ventricular suction, which drives early diastolic
filling, and the role that ventricular twisting and untwisting has in
this. Loss of this normal twisting motion may play an important
part in the abnormal diastolic filling found in HFNEF. Thus, the
problem in HFNEF clearly does not reside in diastole alone, and
the term “diastolic heart failure” has become meaningless (5).
Finally, it is surprising that work that relies almost entirely on
passive measurements of ventricular stiffness at the end of diastole
(6) without any sophisticated assessment of systolic or early
diastolic function can still be used to support the obsolete concept
of “diastolic heart failure.”
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REPLY
We thank Dr. Sanderson for his interest in our study (1). As
more investigators take a fresh look at the matter of heart failure
in the setting of normal ejection fraction (HFNEF), the greater
the number of questions that are being raised as to whether this
condition is always due to diastolic dysfunction. Although
currently an unpopular point of view, an increasing amount of
data indicate that HFNEF and the Doppler echocardiographic
changes found in this condition can occur without diastolic
dysfunction as defined in the classical sense. Dr. Sanderson is
one of many such investigators, and we thank him for coming
forward to express these sentiments. Many abnormalities are
being identified in subsets of HFNEF patients, including those
noted by Dr. Sanderson. It will be of great interest to follow
how these are unraveled to reveal the primary mechanisms
underlying HFNEF so that specific, more effective treatments
can be developed. What is most needed at the present time is
that the cardiology community adopt an open mind with
enhanced receptivity to new ideas about a very important health
problem.
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Vascular Complications
and Arteriotomy Closure Devices
During Percutaneous Coronary Procedures
I read with great interest the study by Nikolsky et al. (1) describing
a meta-analysis of the vascular closure device complication rate as
compared to manual compression. As the investigators describe,
the complication rate with arteriotomy closure devices in diagnos-
tic catheterization appears to be similar between closure device and
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compression. Moreover, the complication rate appears similar for
interventional procedures for the market-leading products, Angio-
Seal and Perclose, with a higher complication rate seen with the
VasoSeal device (1).
As with other interventional technologies, an evolution has
occurred in closure device technology that outpaces the published
data. In our own portfolio of Perclose suture closure products, key
improvements have been seen with each generation of product.
The Closer product was introduced in 1999 and saw a fundamental
change with needles that captured suture from above the arteriot-
omy rather than having a platform where needles were actually
positioned in the artery and delivered suture to the surface. We
believe that the Closer provided a patient safety feature and greater
reliability, which may not have been reflected in the meta-analysis,
which included 15 Perclose-related studies on the older TechStar
and ProStar product lines reported by Nikolsky. A more recent
patient set was examined by Tavris et al. (2), where analysis of the
large ACC-NCDR database of 166,680 patients saw a reduction
in vascular complications and death in patients who had the
Angio-Seal and Perclose vascular closure devices used when
compared to manual compression or compression devices. This
finding was assessed from patient data collected between 2001 and
2002.
Similarly, a meta-analysis may not reflect a change in practice
style or technique, which might be better detected in a randomized
clinical trial or database survey. Of the 15 Perclose studies
examined, only 4 were with 6- to 7-F sheaths; the others were
actually larger sheath sizes, which is uncommon in practice over
the past five to six years. Suture-based devices in particular have
been commonly used in larger-diameter puncture sites. Closure
devices have reduced their size as practice patterns have moved
toward a smaller dimension, and this shift may be reflected in
outcomes seen with the newer devices as well as with manual
compression with or without a compression-assist device.
Despite the criticisms mentioned above, the Nikolsky et al. (1)
study is an important signal for our field. Although no study is
perfect, reports such as those by Nikolsky et al. (1) and Tavris et al.
(2) have shown that the predominant technologies on the market
are equivalent and potentially superior to manual compression in
providing patient comfort and safety. Higher-risk clinical scenarios
have to be considered, especially in the female patient (3); however,
the time may be ripe for more study and a head-to-head random-
ized clinical trial.
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REPLY
We reviewed carefully the comments of Dr. Chou regarding our
recent study (1). A meta-analysis always has several limitations,
which we listed in the respective section of our report and which
Dr. Chou outlines in his letter. The main issue of the multiple
small size, uncontrolled, and often unpublished (as complete
papers) studies in the area of vascular closure devices can be
attributed to the existence of multiple generations of all devices
and to the funding variability (or difficulty to obtain adequate
research grants from industry). Similarly, a database analysis (2) is
also limited by the uncontrolled, rather random (and certainly
nonconsecutive) data entry and the absence of event review and
adjudication by an independent committee. Moreover, Dr. Chou’s
claim that more recent-generation devices are included is a very
reasonable presumption but is not explicitly documented. These
limitations of the way the queried database is set up have nothing
to do with the elegant way the data were handled by Tavris et al.
(2) but still deserve to be outlined.
Therefore, we do not believe that adequate reasons exist to
declare one type of analysis “more meaningful” than the other, but
we certainly endorse the expressed interest by a major industry
stakeholder for a large, randomized study. This is what is needed
the most in this subject.
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Heart Failure Training: Care for
Older Adults With Chronic Heart Failure
Studies by Adamson et al. (1) and Konstam (2) eloquently
highlight the need for heart failure (HF) specialists. As drug and
device therapies for HF are rapidly evolving, it is difficult even for
cardiologists to stay abreast of. Internists, family physicians, and
geriatricians, who treat the vast majority of HF patients, often
underutilize angiotensin-converting enzyme (ACE) inhibitors or
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